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Abstract
Nine isolates of Klebsiella pneumoniae were isolated from a renal transplant patient suffering from recurrent urosepsis over a period of
4 months. Imipenem resistance was detected after imipenem-ertapenem therapy. When treatment was switched to tigecycline the
K. pneumoniae developed resistance to tigecycline (MIC = 8 mg/L). The nine isolates were tested by determination of agar dilution MICs,
phenotypic carbapenemase, extended-spectrum beta-lactamases and metallo-beta-lactamase (MBL) testing and pulsed-ﬁeld gel electro-
phoresis. Polymerase chain reaction and sequencing analysis were employed for identiﬁcation of bla genes and mapping of the integron
carrying the MBL gene. The nine isolates were clonally related and all produced the SHV-12 enzyme. Five MBL-producing isolates
showed imipenem MICs ranging from 2 to 64 mg/L and all were detected by testing with imipenem and EDTA. The ﬁve isolates har-
boured the blaVIM-1 gene. Three isolates showed increased tigecycline MICs (4–8 mg/L). Serial blood cultures obtained on the same day
resulted in a VIM-positive/tigecycline-susceptible and a VIM-negative/tigecycline-resistant K. pneumoniae isolate. No isolate developed
concurrent imipenem and tigecycline resistance. The patient had a persistent urinary tract infection and recurrent bacteraemia caused
by a mixed population of Klebesiella pneumoniae isolates adapting to the selective pressure of antimicrobial therapy at the time. The
present study is a worrisome example of what could happen when an immunocompromised host is subjected to the pressures of anti-
microbial therapy. In addition, we report the ﬁrst treatment-emergent MIC increase of tigecycline from 0.5 to 8 mg/L in K. pneumoniae.
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Introduction
Carbapenems are considered a reliable choice for the treat-
ment of infections caused by extended-spectrum beta-lactam-
ase (ESBL)-producing Klebsiella pneumoniae. The emergence of
strains with reduced susceptibility or resistance to carbapen-
ems is becoming a therapeutic challenge [1]. Southern Europe
seems to be an important focus of metalo-beta-lactamase
(MBL)-producing Gram-negative organisms, including K. pneu-
moniae [2,3]. The most frequent MBLs are IMP and VIM types
[4]. K. pneumoniae VIM producers have been isolated in many
countries, including Greece [5], Italy [6], Germany [7] and
Spain [8,9]. Psichogiou et al. [10] reported the spread of
K. pneumoniae producing both VIM-1 and SHV-5 in the major
hospitals in Greece. Kassis-Chikhani et al. [11] identiﬁed both
SHV-5 and VIM-1 in eight strains of K. pneumoniae in a French
hospital and clinical isolates of K. pneumoniae CTX-M-15,
VIM-4 and CMY-4 producers were identiﬁed in Tunisia [12].
Detection is a challenge for clinical microbiologists because
most of these carbapenemases confer only reduced suscepti-
bility to carbapenems and their possible coexistence with
other beta-lactamases. There are different studies for the
evaluation of methods to identify the MBLs [13,14].
The potential therapeutic use of tigecycline for the treat-
ment of infections caused by carbapenemase-producing En-
terobacteriaceae has been assessed in the report from the
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SENTRY antimicrobial surveillance program [15]. Tigecycline
also showed excellent in vitro activity against K. pneumoniae
producing ESBLs and plasmid-mediated AmpC-type beta-lac-
tamases, or both [16].
Here we report the emergence of MBL activity by acquisi-
tion of the blaVIM-1 gene followed by subsequent acquisition of
resistance to tigecycline in an ESBL-producing strain of
K. pneumoniae. The strain was isolated multiple times over a 4-
month period from the blood and the urine of a kidney trans-
plant patient, who had received multiple courses of antimicro-
bial agents during his illness. No isolate developed concurrent
imipenem and tigecycline resistance. Our aim was to evaluate
the antimicrobial susceptibility proﬁles, the genetic relatedness
and the mechanisms of beta-lactam resistance among the nine
clinical isolates of this multidrug-resistant K. pneumoniae.
Methods
Case report
A 74-year-old man underwent in our hospital a kidney trans-
plant in January 2008. Patient risk factors included: diabetes
mellitus type 2, 7 years dialysis, hypertension, kidney trans-
plantation and previous antibiotic usage. He received cefazolin
1 g 1 h before surgery. In the postoperative period he pre-
sented with fever and was put on levoﬂoxacin treatment
(250 mg/12 h). One week later an extended-spectrum beta-
lactamase (ESBL)-producing Klebsiella pneumoniae (K1) suscep-
tible to imipenem but resistant to ciproﬂoxacin was isolated
from his urine. Levoﬂoxacin administration was suspended
and the patient was put on an imipenem-containing regimen
(250 mg/6 h during 2 weeks). Four days later another isolate
(K2) was obtained, followed by K3 and K4, isolated 1 and
3 weeks later. Because K4 was fully resistant to imipenem,
treatment was changed to tigecycline (100 mg for the ﬁrst
dose and 50 mg/12 h for 1 week). One week later K5 was
obtained from two sets of blood cultures; it was resistant to
tigecycline, as was K6 isolated 4 days later. The patient’s renal
function slowly improved with negative blood cultures; how-
ever, urine cultures continued to be positive. The patient was
discharged in May 2008, after a hospitalization period of
4 months. Two weeks later the patient developed an allograft
dysfunction and was readmitted to the hospital. Urine cul-
tures were positive for an ESBL-producing K. pneumoniae and
antimicrobial treatment with ertapenem 1 g/24 h was initi-
ated. Three days later K7 and K8 were isolated from two
blood cultures taken on the same day, with different suscepti-
bility proﬁles: K7 displayed an increase in the MIC of imipe-
nem while K8 showed an increase in the MIC of tigecycline.
One week later K9 was obtained from two new blood cul-
tures, with the same susceptibility proﬁle as K7. The grafted
kidney was removed 1 month later.
Bacterial isolates
The study includes nine Klebsiella pneumonie strains isolated
from urine (four strains) and blood cultures (ﬁve strains) of
the patient during a 4-month period in 2008. Identiﬁcation and
initial antimicrobial susceptibility were performed by the auto-
mated system Vitek 2 (bioMe´rieux, Marcy-l’Etoile, France).
Antimicrobial susceptibility and phenotypic testing
MICs of eight beta-lactamic agents, amoxicillin-clavulanic acid
and ceftazidime (GSK, Madrid, Spain), cefoxitin and cefotaxime
(Laboratorios Normon S.A, Madrid, Spain), aztreonam (Sigma-
Aldrich Quimica S.A., Madrid, Spain), cefepime (Bristol Myers,
Madrid, Spain), imipenem and ertapenem (MSD, Spain), and six
non-beta-lactamic agents, ciproﬂoxacin (Bayer, Barcelona,
Spain), tigecycline (Pﬁzer, Madrid, Spain), gentamicin, amikacin
and nitrofurantoin (Sigma-Aldrich Quimica SA) and fosfomycin
(Zambon, Barcelona, Spain), were determined by the agar dilu-
tion method on freshly prepared Mueller–Hinton agar accord-
ing the Clinical and Laboratory Studies Institute (CLSI)
guidelines [17]. For determining the MICs of fosfomycin the Mu-
eller-Hinton agar was supplemented with 25 mg/L of G-6-P
(glucose-6-phosphate; Sigma-Aldrich Quimica S.A). MICs of
colistin were determined by Etest (bioMe´rieux) performed on
Mueller–Hinton agar (MH2) from bioMe´rieux. This method
was also used for conﬁrming tigecycline MICs. The results were
interpreted according to the CLSI [17]. European Committee
on Antimicrobial Susceptibility Testing (EUCAST) breakpoints
were applied for fosfomycin in non-urinary isolates (http://
www.eucast.org/clinical_breakpoints/; last accessed 27 April
2010).
Breakpoints for tigecycline were those of the US Food
and Drug Administration (£2 and ‡8 mg/L for susceptible
and resistant, respectively). E. coli ATCC 25922, E. coli
ATCC 35218 and P. aeruginosa ATCC 27853 were used as
control strains in susceptibility assays.
ESBL production was initially assessed by the disk diffusion
phenotypic conﬁrmatory test [17]. MICs of cefotaxime, ceft-
azidime and aztreonam in the presence of 4 mg/L of clavulan-
ic acid were also determined. According to the CLSI
conﬁrmatory test, MICs that decreased by three dilutions or
more were suggestive of the presence of an ESBL [17].
Carbapenemase production was screened by the modi-
ﬁed Hodge test and the presence of MBL was detected by
the combined-disk (CD) test with imipenem and EDTA
(10 lL, 100 mM). The test was considered positive when
an increase of ‡5.0 mm in the size of inhibition zone was
observed [14].
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Polymerase chain reaction (PCR) assays and DNA sequenc-
ing
The detection of broad-spectrum beta-lactamase genes (VIM,
IMP, TEM, SHV and CTX-M types) was sought by PCR as
described elsewhere [18,19]. Isolates from our collection that
were previously characterized were used as controls in the
PCR assays. For integron mapping, PCR assays combining
primers speciﬁc for conserved 5¢-CS and 3¢-CS sequences with
primers for blaVIM, aacA, dfr, aadA, qacE1 and sul genes were
performed. The Expand Long Template PCR System (Roche
Diagnostics, Mannhein, Germany) was used for long-range
PCR. Sequencing was performed in a thermal cycler with use
of the dRhodamine Dye Terminator Cycle Sequencing Ready
Reaction kit (Applied Biosystems, Foster City, CA, USA).
Clonal relatedness
Chromosomal DNA was digested with XbaI and subject to
pulsed-ﬁeld gel electrophoresis (PFGE). The electrophoresis
conditions used were 22 h at 6 V/cm with initial and ﬁnal
pulse times of 5 and 40 s, respectively. The temperature was
set at 14C with the use of the CHEF-DRIII system (Bio-Rad
Birmingham, UK). The banding patterns were compared
based on the criteria described by Tenover et al. [20]. Two
unrelated strains were used as controls.
Results
Antimicrobial susceptibility patterns of K. pneumoniae iso-
lates
The MICs of eight beta-lactamic agents for the nine K. pneu-
moniae isolates are shown in Table 1. The nine isolates
were characterized by reduced and variable susceptibility to
beta-lactamic agents. The initial isolate K1 was resistant to
extended-spectrum cephalosporins and aztreonam, but sus-
ceptible to imipenem (MIC = 0.12 mg/L), suggesting an ESBL
producer. An increase in the MICs of imipenem was ﬁrst
noted in isolate K2 (MIC = 2 mg/L) and subsequently in K3
with the same resistance proﬁle. Isolate K4 was fully resis-
tant to imipenem (MIC = 64 mg/L) and to all the other
beta-lactams. K5 and K6 were recovered later; both had
the same resistance proﬁle and were also susceptible to
imipenem.
More than 2 months later, in May 2008, K7 and K8 were
recovered from two distinct blood cultures. K7 showed
reduced susceptibility to imipenem, but K8 demonstrated
susceptibility to imipenem and resistance to tigecycline. K9,
from two new distinct blood cultures, showed a similar sus-
ceptibility pattern to K7.
The MICs for the six non-beta-lactamic agents are also
shown in Table 1. All the isolates were resistant to cipro-
ﬂoxacin and susceptible to nitrofurantoin. Most of them
were resistant to gentamicin but susceptible to amikacin. All
isolates, except two strains (K4 and K8), were fosfomycin
susceptible. Agar dilution susceptibility test revealed that six
strains were susceptible to tigecycline, with MIC values
between 0.5 and 1 mg/L, two showed resistance with MIC
values of 8 mg/L and one showed an intermediate level of
resistance. All the strains were susceptible to colistin, show-
ing a MIC of 0.38 mg/L. With respect to the main antimicro-
bial agents tested, the nine isolates showed four phenotypic
patterns: Pattern 1, K1, ESBL producer, susceptible to imipe-
nem and tigecycline; Pattern 2, K2, K3, K4, K7 and K9,
increased MIC of imipenem, susceptible to tigecycline; Pat-
tern 3, K5 and K6, ESBL producer, resistant to tigecycline;
and Pattern 4, K8, ESBL producer, intermediate resistance to
tigecycline and susceptible to amikacin (MIC = 1 mg/L) and
gentamicin (MIC = 0.5 mg/L).
TABLE 1. Minimal inhibitory concentrations of selected antimicrobial agents against nine K. pneumoniae urine and blood iso-
lates
Date
(Month/day) Origina Isolate
Antimicrobial agent MIC (mg/L)
A/C FOX CTX CAZ AZT CPM IPM ETP CIP TGC GM AK FOS NIT
2/14 U K1 32 8 8 128 128 4 0.12 0.12 32 1 >128 8 8 16
2/18 U K2 64 128 64 >256 128 32 2 2 32 1 >128 16 8 16
2/21 U K3 64 128 64 >256 128 32 2 4 32 1 >128 16 8 16
3/5 U K4 64 >128 >256 >256 8 128 64 128 32 0.5 128 2 128 32
3/12 B(2)a K5 16 32 8 128 128 8 0.12 0.12 64 8 >128 16 16 32
3/16 B(2) K6 16 32 8 128 128 8 0.06 0.06 64 8 >128 8 16 32
5/29 B(1)b K7 64 128 64 >256 128 32 2 2 32 1 >128 32 8 16
5/29 B(1)b K8 8 16 16 16 8 8 0.12 0.06 32 4 0.5 1 128 32
6/5 B(2) K9 64 128 128 >256 64 64 2 1 32 1 >128 8 16 16
A/C, amoxicillin-clavulanic acid; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; ATM, aztreonam; CPM, cefepime; IPM, imipenem; ETP, ertapenem; CIP, ciproﬂoxacin;
TGC, tigecycline; GM, gentamicin; AK, amikacin; FOS, fosfomycin; NIT, nitrofurantoin; AZT, aztreonam; U, urine; B, blood.
aThe strain was isolated from two blood cultures.
bEach strain was isolated from a different blood culture taken on the same day.
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Phenotypic conﬁrmation of ESBL and carbapenemase pro-
duction
The MICs of the extended-spectrum cephalosporins and azt-
reonam were compared with the MIC reduction of them in
the presence of 4 mg/L of clavulanic acid. This test, when
done with cefotaxime and ceftazidime, yielded positive
results for K1, K5, K6 and K8 isolates only, suggesting ESBL
activity, whereas testing with aztreonam yielded positive
results for all the isolates. The results are shown in Table 2.
Carbapenemase production was positive for isolates K2,
K3, K4, K7 and K9, with all displaying susceptibility pattern 2
(IMP resistance or with reduced susceptibility). The imipe-
nem-EDTA combination-disk test was also positive for these
isolates, suggesting the production of an MBL (Table 2).
Characterization of beta-lactamases and integron analysis
PCR analysis and amplicon sequencing revealed that all nine
isolates contained a blaSHV-12 determinant. In addition, all the
MBL-producing isolates contained a blaVIM-1 gene. All isolates
except K4 and K8 contained a blaTEM-1 gene (Table 2). Analy-
sis of the blaVIM-1-containing integron was performed in the
isolate K4. The integron variable region consisted of blaVIM-1,
orfII and orfIII genes; orfII and orfIII showed 99% similarity to
K. pneumoniae gene bank accession number DQ153218.1.
Clonal relatedness
All isolates were clonally related. The VIM-1-producing
K. pneumoniae isolates, with the susceptibility Pattern 2, dem-
onstrated identical XbaI PFGE pattern (A). Three subtypes of
pattern A were detected among the non-VIM-1-producing
isolates (Fig. 1). The PFGE patterns correlated with the sus-
ceptibility patterns: PFGE pattern A1 with Pattern 1 (K1,
ESBL producer, susceptible to imipenem and tigecycline);
PFGE pattern A2 with Pattern 3: (K5 and K6, ESBL pro-
ducer, resistant to tigecycline) and PFGE pattern A3 with
Pattern 4: (K8, ESBL producer, intermediate resistance to
tigecycline and susceptible to amikacin and gentamicin).
Discussion
Here we report the emergence of MBL activity by acquisi-
tion of the blaVIM-1 gene following carbapenem therapy, in an
ESBL-producing strain of K. pneumoniae isolated from the
urine of a kidney transplant patient. The initial isolate was an
TABLE 2. Phenotypic conﬁrmatory tests for beta-lactamase production, PCR ampliﬁcation and pulsed-ﬁeld gel electrophoresis
patterns in nine K. pneumoniae isolates
Isolate
Phenotypic conﬁrmatory tests for beta-lactamase production
Beta-lactamases
PFGEc
Hodge
test
CDa
test
MIC decrease/ESBL interpretationb
CTX CTX/C ESBL CAZ CAZ/C ESBL AZT AZT/C ESBL blaSHV-12 blaTEM-1 blaVIM-1
K1 ) ) 8 0.06 + 128 0.5 + 128 0.12 + + + ) A1
K2 + + 64 64 ) >256 >128 ) 128 0.12 + + + + A
K3 + + 64 128 ) >256 >128 ) 128 0.12 + + + + A
K4 + + >256 >128 ) >256 >128 ) 8 0.25 + + ) + A
K5 ) ) 8 0.5 + 128 1 + 128 0.25 + + + ) A2
K6 ) ) 8 0.5 + 128 1 + 128 0.12 + + + ) A2
K7 + + 64 128 ) >256 >128 ) 128 0.12 + + + + A
K8 ) ) 16 0.5 + 16 1 + 8 0.25 + + ) ) A3
K9 + + 128 64 ) >256 >128 ) 64 0.12 + + + + A
aCD test, combined-disk test with imipenem and EDTA (10 lL, 100 mM).
bCTX/C, CAZ/C and AZT/C: MIC determined in the presence of 4 mg/L of clavulanic acid. CTX, cefotaxime; CAZ, ceftazidime; AZT, aztreonam. The MICs reduced ‡3 dilu-
tions were interpreted as positive.
cAll isolates showed subtypes of pattern A.
ESBL, extended-spectrum beta-lactamases.
λ K1 K2 K3 K6K5K4   C  D K7 K8 K9Strains
PFGE patterns A1 A A A A2 A2 - - A A3 A
λ
FIG. 1. Pulsed-ﬁeld gel electrophoresis restriction patterns of Klebsi-
ella pneumoniae isolates (K1–K9). C and D are unrelated isolates.
The letter A designates the major pattern. All isolates showed sub-
types of the pattern A. k, lambda marker.
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SHV-12 and TEM-1 producer, but gradually, following an im-
ipenem-containing regimen, became resistant to imipenem
(MIC = 64 mg/L), due to the presence of the bla-VIM-1 gene,
and when treatment was switched to tigecycline, the K. pneu-
moniae became resistant to tigecycline while the resistance
to imipenem was lost. Two months later treatment with er-
tapenem was initiated and the K. pneumoniae increased its
carbapenem MIC again due to the presence of the bla-VIM-1
gene. Spread of acquired MBLs among K. pneumoniae is
increasing worldwide, mainly in Europe [3]. Recently, VIM-1-
producing strains were found in Greece [5], France [11] and
Spain [8]. The presence of VIM-1 plus an ESBL in K. pneumo-
niae has also been reported in Greece [10] and in a clonal
outbreak in Spain [9]. The simultaneous presence, following
imipenem therapy, of an ESBL and a carbapenemase in
K. pneumoniae has been documented [21]. However, we
describe here the in vivo development of carbapenem resis-
tance under antibiotic selective pressure by acquisition of
the blaVIM-1 gene. It appears that a mixed population of VIM-
1-positive/negative isolates coexisted in the patient but only
the dominant isolate, adapting to the antimicrobial pressure
at the time, was obtained each time. In vivo evolution of
resistance has been reported previously in a strain of Escheri-
chia coli, but the carbapenem-hydrolyzing enzyme gene was
bla KPC-3 [22].
The ﬁve K. pneumoniae strains with the VIM-1 gene dem-
onstrated the same PFGE type but showed imipenem MICs
ranging from 2 to 64 mg/L (susceptible to high-level resis-
tance). Differences in the carbapenem resistance levels
among isolates of the same PFGE type were also observed in
other studies [5,23]. Using the new CLSI breakpoints (M100-
S20U-2010) [24] isolates with an imipenem MIC of 2 lg/mL
could be properly detected as imipenem intermediate and
ertapenem resistant. In these low-level resistant isolates
standard doses of imipenem could be one reason for the
selection of highly resistant strains.
Most of our isolates were resistant to aztreonam,
although this antibiotic is not hydrolyzed by MBLs [1]. In our
experience the synergy test to detect ESBLs yielded a posi-
tive result only with aztreonam for this VIM-1-producer iso-
late. As all of them were SHV-12 producers, the presence of
an ESBL can be masked by the expression of an MBL, we
suggest the use of aztreonam in the phenotypic conﬁrmatory
method instead cefotaxime or ceftazidime.
As was stated before, when treatment was changed to
tigecycline, tigecycline-resistant (MIC = 8 mg/L) K. pneumo-
niae isolates K5 and K6 were sequentially recovered in blood
cultures 1 week later (on 12 and 16 March). The clinical use
of tigecycline for the treatment of infections with these
MBL-producing organisms has been reported [25]; a
treatment-emergent tigecycline MIC increase (from 0.75 to
2 mg/L) among a KPC-producing K. pneumoniae strain during
therapy has also been reported [26]. Our patient was dis-
charged from the hospital but because he developed an allo-
graft dysfunction, he was readmitted to the hospital. An
ESBL- producer K. pneumoniae was isolated from his urine
and 3 days later K8 with a MIC of 4 mg/L for tigecycline was
isolated from blood cultures. It seems that although bactera-
emia was treated successfully, the urinary tract infection
recurred in association with a treatment-emergent tigecy-
cline resistance. As has been reported by other authors [27],
clinicians should be aware of the potential occurrence of this
treatment-emergent tigecycline resistance, especially when
the urine is the main source of bacteria in blood. Some
strains of Enterobacteriaceae that showed decreased suscep-
tibility to tigecycline have been isolated, including clinical
K. pneumoniae isolates [28,29]. Nevertheless, to our knowl-
edge, a treatment-emergent MIC increase of tigecycline from
0.5 to 8 mg/L has not been described.
In this study we also detected the coexistence in the blood
of the patient of two K. pneumoniae (one in each set of two
blood cultures) with a different susceptibility proﬁle; one of
them had the blaVIM-1 gene, resistant to imipenem, and the
other had a MIC of 4 mg/L for tigecycline and was carbapenem
susceptible. Two strains with different susceptibility proﬁles
have been co-isolated from blood in the past [30]. This obser-
vation reinforces the idea that a mixed population of VIM-
positive/negative and tigecycline-resistant/susceptible isolates
coexisted in the patient. We report also that no isolate was
resistant to both agents, and resistance to tigecycline emerged
only in the bacteria without the blaVIM-1 gene.
The acquisition of new resistance genes makes mixed pop-
ulations with a tremendous ability to adapt under the selec-
tive pressure of antimicrobial therapy; consequently, the
patient had a persistent urinary tract infection and a recur-
rent bacteraemia.
This collection of urine and blood isolates from the same
patient during his clinical course is a worrisome example of
what could happen when an immunocompromized host is
put under substantial antimicrobial pressure.
Bacterial urinary tract infections are frequently associated
with early-onset chronic rejection and may lead to reduced
transplantation survival [31]. Therefore the emergence of
infections due to multiresistant K. pneumoniae reinforces the
importance of strict infection control practices.
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